The global Alpha-Emitter Radioligand Therapy (α-RLT) market is at the forefront of a paradigm shift in oncology. Unlike traditional beta-emitters (like Lutetium-177), alpha-emitters deliver high-energy radiation over a much shorter range—typically just a few cell diameters—allowing for devastating "double-strand breaks" in cancer DNA while significantly sparing...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek